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Background: Lung cancer is considered a terminal illness with a five-year survival rate of about 16%. Informed
decision-making related to the management of a disease requires accurate prognosis of the disease with or
without treatment. Despite the significance of disease prognosis in clinical decision-making, systematic assessment
of prognosis in patients with lung cancer without treatment has not been performed. We conducted a systematic
review and meta-analysis of the natural history of patients with confirmed diagnosis of lung cancer without active
treatment, to provide evidence-based recommendations for practitioners on management decisions related to the
disease. Specifically, we estimated overall survival when no anticancer therapy is provided.
Methods: Relevant studies were identified by search of electronic databases and abstract proceedings, review of
bibliographies of included articles, and contacting experts in the field. All prospective or retrospective studies
assessing prognosis of lung cancer patients without treatment were eligible for inclusion. Data on mortality was
extracted from all included studies. Pooled proportion of mortality was calculated as a back-transform of the
weighted mean of the transformed proportions using the random-effects model. To perform meta-analysis of
median survival, published methods were used to pool the estimates as mean and standard error under the
random-effects model. Methodological quality of the studies was examined.
Results: Seven cohort studies (4,418 patients) and 15 randomized controlled trials (1,031 patients) were included in the
meta-analysis. All studies assessed mortality without treatment in patients with non-small cell lung cancer (NSCLC). The
pooled proportion of mortality without treatment in cohort studies was 0.97 (95% CI: 0.96 to 0.99) and 0.96 in
randomized controlled trials (95% CI: 0.94 to 0.98) over median study periods of eight and three years, respectively.
When data from cohort and randomized controlled trials were combined, the pooled proportion of mortality was 0.97
(95% CI: 0.96 to 0.98). Test of interaction showed a statistically non-significant difference between subgroups of cohort
and randomized controlled trials. The pooled mean survival for patients without anticancer treatment in cohort studies
was 11.94 months (95% CI: 10.07 to 13.8) and 5.03 months (95% CI: 4.17 to 5.89) in RCTs. For the combined data
(cohort studies and RCTs), the pooled mean survival was 7.15 months (95% CI: 5.87 to 8.42), with a statistically
significant difference between the two designs. Overall, the studies were of moderate methodological quality.
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Conclusion: Systematic evaluation of evidence on prognosis of NSCLC without treatment shows that mortality is very
high. Untreated lung cancer patients live on average for 7.15 months. Although limited by study design, these findings
provide the basis for future trials to determine optimal expected improvement in mortality with innovative treatments.
Keywords: Best supportive care, Natural history, Meta-analysis, Palliative care, PlaceboBackground
Cancer is a major public health concern globally. It is
the most frequent cause of death in economically devel-
oped countries [1]. Among all cancers, lung cancer is
the leading cause of cancer deaths worldwide [2]. In the
United States, approximately 221,130 new cases of lung
cancer (14% of all cancer diagnoses) are expected in
2011 out of which 156,940 deaths (27% of cancer deaths)
are estimated due to lung cancer [3]. Given the incurable
nature of lung cancer, it is considered a terminal illness
with a five-year survival rate of approximately 16% [3].
Patients diagnosed with terminal illness such as lung
cancer confront several decisions related to management
of the disease. Opting for treatment (for example, chemo-
therapy, radiotherapy, or surgery) instead of palliation, or
vice versa, is one such critical decision. Depending on the
stage of the disease, potential benefits of anticancer ther-
apy intended to palliate specific tumor-related symptoms
may be at the expense of treatment-related harms and the
inconvenience associated with undergoing treatment. At
other times, palliative care (for example, pain medications
or low dose radiotherapy) [4] rather than anticancer ther-
apy may be preferable. Informed decision-making related
to the management of a terminal disease thus requires ac-
curate prognosis of the disease with or without treatment.
Briefly, prognosis refers to the likelihood of an individual
developing a particular health outcome over a given
period of time, based on the individual’s clinical and non-
clinical profile [5]. Accurate assessment of prognosis is key
to informed decision-making. For example, if a patient is
diagnosed with a terminal illness such as lung cancer, a
prognostic question of critical concern to the patient, fam-
ily, and the physician is how long the patient is expected
to live. Other important outcomes may include disease
progression, health-related quality of life, and treatment-
related harms. Reliable prognostication of life expectancy
can prevent subjecting patients to costly and unnecessary
treatment for an unduly long period before transitioning
to hospice care [6]. This in turn can help patients and
their families prepare for the impending events and plan
for the patient’s remaining lifespan [7]. Accurate prognos-
tic information can also help physicians decide on choice
of curative versus palliative treatments. For instance, if evi-
dence shows no effect of curative treatment on disease
progression, significant treatment-related harms can be
avoided in favor of palliative treatments [7]. It can helpinvestigators avoid optimism bias, the ‘unwarranted belief
in the efficacy of new therapies’ [8] or making ‘overly opti-
mistic assumptions regarding treatment benefits when
designing RCTs’ [9]. Accurate disease prognosis thus
underpins all management decisions related to the disease,
including choice of treatment, planning of supportive care,
as well as allocation of resources.
Despite the significance of disease prognosis in clinical
decision-making, systematic assessment of prognosis in
patients with lung cancer without treatment has not been
performed. We are aware of only one narrative review on
the subject [4,10]. Accordingly, this systematic review was
undertaken to assess the survival of patients with a con-
firmed diagnosis of lung cancer without active treatment.
Specifically, our aim was to estimate overall survival in
lung cancer when no anticancer therapy is provided.
Methods
This systematic review was conducted as per the methods
elaborated in a protocol that was developed a priori. The
results are reported according to PRISMA (Preferred
Reporting Items for Systematic Reviews and Meta-Analyses)
statement [11]. An ideal study design to assess the natural
history of a terminal disease such as lung cancer is a co-
hort study. Specifically, an inception cohort, whereby a
well-defined group of patients at the same disease stage is
assembled at first diagnosis and followed for a defined
period of time [12-14]. However, given the availability of
treatments for lung cancer in recent years, it would be un-
ethical and logistically challenging to conduct such a
study. An alternative approach is to assess prognosis from
retrospective lung cancer registries, case series or from the
control arm of individual RCTs that compare active treat-
ment with either no treatment, placebo, or best supportive
care [5,15].
Study eligibility
In this review, any retrospective or prospective cohort
study assessing prognosis in lung cancer without treatment
and any RCT assessing the role of treatment versus no
treatment, were eligible for inclusion. A study was eligible
for inclusion irrespective of language or publication type.
Search strategy
We conducted a systematic search of MEDLINE and
Cochrane library electronic databases, proceedings of major
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identify all relevant studies. To retrieve lung cancer prog-
nosis studies in PubMed, we employed search strategies
suggested by Wilczynski [16] that optimizes search sensi-
tivity and specificity. Search details used included: ("lung
neoplasms" [MeSH Terms] AND "prognosis" [All Fields]
AND "cohort" [All Fields] AND "mortality" [Subheading]
OR "natural course" [All Fields] OR "mortality" [All Fields]
OR "survival" [All Fields] OR "survival" [MeSH Terms]).
To retrieve RCTs in PubMed, we employed strategies sug-
gested by Haynes [17] with the following search details:
("lung neoplasms" [MeSH Terms] AND "randomized con-
trolled trial" [Publication Type]) AND ("palliative care"
[All Fields] OR "hospice care" [All Fields] OR "supportive
care" [All Fields] OR "best supportive care" [All Fields] OR
"placebo" [All Fields] OR "symptomatic treatment" [All
Fields] OR "no chemotherapy" [All Fields] OR "no treat-
ment" [All Fields]). In the Cochrane library, we utilized a
free text search using the term “Lung cancer” to identify
RCTs focusing on lung cancer. We manually searched
abstracts of the American Society of Clinical Oncology
and American Society of Hematology meetings and uti-
lized the snowballing procedure to identify other relevant
studies. Studies published until June 2011 were included.
No restrictions were made regarding the language of the
publication.
Inclusion and exclusion criteria
A prospective or retrospective cohort study assessing over-
all survival as an outcome in lung cancer patients without
treatment was eligible for inclusion. A RCT was included
if it enrolled patients with confirmed diagnosis of lung
cancer, compared treatment versus no treatment (for ex-
ample, supportive care, best supportive care, palliative
care, placebo, and so on), and assessed overall survival as
an outcome. A study in which patients had anticancer
treatment prior to enrollment and subgroup analyses were
excluded. Additionally, RCTs comparing two active treat-
ments were excluded. Two reviewers read the titles and
abstracts of identified citations to identify potentially eli-
gible studies. Full text of potentially relevant reports were
retrieved and examined for eligibility. Disagreements about
study inclusion or exclusion were resolved via discussion
until a consensus was reached.
Data extraction
Data extraction was performed using a standardized data
extraction form. Two reviewers independently extracted
the following information from each included study: num-
ber of patients enrolled, number of deaths, median sur-
vival, funding source (industry versus public, and so on),
type of centers involved (single versus multicenter, and so
on.), patient demographics, patients’ baseline clinical char-
acteristics, and type of control arm (for RCTs only). Forcohort studies, we extracted data on the number of deaths
and total number of patients diagnosed with lung cancer.
For RCTs, we extracted data on the number of deaths (all-
cause mortality) and number of participants randomized
to the control arm.
Assessment of methodological quality
To evaluate the methodological quality of included stud-
ies, a modified checklist of predefined criteria was de-
veloped on four methodological domains pertinent to
minimization of bias. This modified checklist uses applic-
able elements from existing tools (Quality in Prognosis
Studies tool [18], Evidence-Based Medicine Group criteria
for prognostic studies [19], Newcastle-Ottawa Quality As-
sessment Scale [20], Cochrane Collaboration risk of bias
criteria [21]) and related studies (Hudak et al. [22] and
Altman [23]). The four domains included ‘participation
bias’ (extent to which study sample represents the popula-
tion of interest on key characteristics), ‘attrition bias’ (ex-
tent to which loss to follow-up of the sample was not
associated with key characteristics), ‘outcome measure-
ment’ (extent to which outcome of interest is adequately
measured in study participants), ‘data analysis’ and ‘report-
ing’ (extent to which statistical analysis and data reporting
are appropriate for the study design). The modified check-
list contains 11 items for cohort studies and 14 items for
RCTs. For each item, a study either fulfilled a certain cri-
terion (scored ‘Yes’) or failed to fulfill the criterion (scored
‘No’). To assess methodological quality of the studies
included, we focused on the proportion that fulfilled each
quality criterion (Table 1).
Statistical analysis
Data synthesis was conducted according to the study de-
sign separately as well as combined in the final stage
(that is, retrospective cohort and RCT). For the purpose
of meta-analysis, we used methods by Stuarts et al. [24] to
transform the proportions into a quantity according to the
Freeman-Tukey variant of the arcsine square root trans-
formed proportion. The pooled proportion was calculated
as a back-transform of the weighted mean of the trans-
formed proportions, using the random-effects model. To
perform meta-analysis of median survival, we used pub-
lished methods [25] to pool the estimates as mean survival
and standard error under the random effects model. That
is, using median survival and range reported in Kaplan-
Meier curve, we converted these estimates into mean
survival and standard error. Heterogeneity of treatment
effects between trials was assessed using the I-squared stat-
istic [21] with the following thresholds for I-squared statis-
tic values: low (25% to 49%), moderate (50% to 74%), and
high (≥75%) [26]. We explored the potential causes of het-
erogeneity by assessing the differences between subgroups
using the test of interaction. We assessed robustness of the
Table 1 Methodological quality of lung cancer prognosis studies
Study Design/Domain/Criterion Criteria fulfilled
n/N %
Cohort studies (11 items)
Participation bias
A Population of interest is adequately described for key characteristics [15] 7/7 100
B Study setting and geographic location is adequately described [15] 7/7 100
C Baseline sample is adequately described for key characteristics [15] 4/7 57
D Inclusion and exclusion criteria are adequately described [15] 5/7 71
E There is adequate participation in the study by all eligible patients [15] 7/7 100
Attrition bias
F Follow-up is sufficiently long for outcome to occur (≥6 months) [16,18,19,46] 6/7 86
G Patients with missing data were reported [15,17] 7/7 100
Outcome measurement
H Definition of outcome is provided a priori [15] 7/7 100
I Objective definition of outcome is provided [15,16,18,19] 7/7 100
Data analysis and reporting
J Alpha error and/or beta error is specified a priori 2/7 29
K Frequencies of most important data (for example, outcomes) are presented [18,19,47] 7/7 100
Randomized controlled trials (14 items)
Participation bias
L Population of interest is adequately described for key characteristics [15] 15/15 100
M Study setting and geographic location is adequately described [15] 7/15 47
N Baseline sample is adequately described for key characteristics [15] 14/15 93
O Inclusion and exclusion criteria are adequately described [15] 14/15 93
P Patients were balanced in all aspects except the intervention 15/15 93
Attrition bias
Q Follow-up is sufficiently long for outcome to occur (≥6 months) [16,18,19,46,48] 8/15 53
R Proportion of sample completing the study is adequate (≥80%) [15,16,18,47,49,50] 9/15 60
S Description of withdrawal (incomplete outcome data) is provided [15,17] 15/15 100
T Characteristics of drop-outs versus completers is provided [15] 2/15 13
Outcome measurement
U Definition of outcome is provided a priori [15] 15/15 100
V Objective definition of outcome is provided [15,16,18,19] 15/15 100
Data analysis and reporting
W Alpha error and/or beta error is specified a priori 7/15 47
X Data analysis was based on intention-to-treat analysis principle [17] 9/15 53
Y Frequencies of most important data (for example, outcomes) are presented [18,19,47] 15/15 100
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A flow diagram depicting the literature search process
based on PRISMA [11] is shown in Figure 1. Initial search
identified 1,562 potentially relevant citations excluding 71
duplicates. After initial screening of titles and abstracts,1,489 records were not relevant for reasons depicted in
Figure 1 and were excluded. Further assessment of full
texts of remaining 73 studies led to exclusion of 51 stud-
ies. Altogether, 22 studies met the pre-defined inclusion
criteria: 7 were retrospective cohort studies [20,28-33] and
15 were RCTs [34-48].
Study characteristics
We did not find any inception cohort study or prospect-
ive cohort study assessing prognosis of patients with
lung cancer without treatment. The seven retrospective
Figure 1 A flow diagram depicting the literature search process.
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RCTs enrolled 1,031 patients. Altogether, the 22 studies
included 5,449 patients. All studies assessed prognosis in
patients with NSCLC and were published between 1973
and 2009 (Table 2).
Cohort studies
The median sample size in the cohort studies was 131
patients (range: 39 to 2,344 patients) with a median study
period of 8 years (range: 5 to 13 years). Fifty-seven percent
(4/7) and 29% (2/7) of the studies reported number of
patients with stage I and stage II NSCLC, respectively.
Forty-three percent (3/7) of the studies reported patients’
cancer histology. Seventy-one percent (6/7) of the studies
reported patient’s gender. Forty-three percent (3/7) of the
studies reported median age. Forty-three percent (3/7) of
the studies were conducted at single institutions, 43% (3/7)
were at multicenter national institutions, and 14% (1/7) of
the studies had unspecified study location. Twenty-nine
percent (2/7) of the studies were publicly funded, 14%
(1/7) were funded by both public and industry, and 57%
(4/7) had not specified funding sources.
RCTs
The median number of patients enrolled in the RCTs was
61 patients (range: 17 to 176 patients) with a median study
period of 3 years (range: 1 to 7 years). Median follow-up
was reported in 33% (5/15 of RCTs) and ranged between
2.7 and 43 months. Seventy-three percent (11/15) of the
studies reported number of patients with stage III/IV
NSCLC. Seventy-three percent (13/15) of the studies
reported patients’ cancer histology. Eighty-seven percent(13/15) of the RCTs reported patient’s gender and median
age. Twenty percent (3/15) of the RCTs were conducted at
single institutions, 27% (4/15) were multicenter national
studies, 20% (3/15) were multicenter international studies,
and 33% (5/15) did not specify study locations. Seven
percent (1/15) of the RCTs were funded by the public, 33%
(5/15) by industry, 7% (1/15) by both the public and indus-
try, and 53% (8/15) had unspecified funding sources.
Types of control in RCTs
Three studies described best supportive care as comprising
‘symptomatic or palliative treatment excluding chemother-
apy’ [49], ‘palliative radiotherapy, antibiotics, and corticos-
teroids’ [35], ‘palliative radiotherapy, opioid analgesics, and
psychosocial support’ [42], or ‘radiation therapy, pain
medication, nutritional and psychological support, thora-
cocentesis and/or tube thorascopy’ [48]. Three studies
described supportive care as comprising ‘analgesics, an
antitussive, relief of increased intracranial pressure, pallia-
tive radiotherapy, treatment of infections and pleural effu-
sions’ [35], ‘symptomatic irradiation to involved fields’ [36],
or ‘palliative radiation, analgesics, and psychosocial/nutri-
tional support’ [40]. Palliative care consisted of ‘radiother-
apy, antibiotics, cough suppressants, and analgesics’ [38].
Symptomatic treatment included ‘glucocorticosteroids and
anabolic steroids’ [43]. No descriptions were provided for
placebo and ‘no treatment’.
Methodological quality
Cohort
All seven cohort studies fulfilled 64% (7/11) of the quality
criteria (Table 1). That is, adequate description of the




Disease Stage Histology Male Median
Age
(years)
I II squamous adeno large-cell
(a) Cohort studies
Raz 2007 1432 13 1432 NR 460 419 89 747 74
Wisnivesky 2007a 2344 8 NR NR NR NR NR 1292 NR
Chadha 2005 39 11 23 13 18 88 5 4 77
Henschke 2003 131 7 131 NR NR NR NR NR NR
McGarry 2002a 49 5 NR NR NR NR NR 49 NR
Vrdoljak 1994 130 7 55 56 61 35 34 120 60
Hyde 1973 293 8 NR NR NR NR NR NR NR
Total/(Range) 4418 (5 to 13) 1641 68 539 542 128 2211
(b) RCTs III IV
Goss 2009c 101 2 (0.23) 17 84 25 46 11 61 76
Anderson 2000 150 2 92 58 NR NR NR 91 64
ELVIS 1999c 78 1 (1.08) 22 56 33 29 3 69 74b
Cullen 1999c 176 8 (2.17) 88 88 103 42 6 122 64
Thongprasert 1999 98 4 49 49 31 49 12 NR 60
Helsing 1998c 26 5 (3.33) 3 23 5 17 4 18 65
Cartei 1993 50 7 NR 50 25 17 8 36 57
Leung 1992c 66 4 (3.58) 58 NR 31 18 7 48 62
Cellerino 1991 61 3 61 NR 38 18 5 59 62
Quoix 1991 22 3 NR 22 NR NR NR NR NR
Kaasa 1991 43 3 NR 43 16 16 11 31 62b
Ganz 1989 26 2 NR 26 9 17 NR 23 NR
Rapp 1988 50 3 50 NR 12 24 12 38 58
Cormier 1982 17 2 17 NR 8 2 6 16 60
Laing 1975 67 2 15 20 23 5 9 59 64
Total/(Range) 1031 (1 to 8) 472 519 359 300 94 671 (57 to 76)
N = Sample size or number of participants enrolled; NR = data not reported; adeno, = adenocarcinoma; squamous, = squamous cell carcinoma; large-cell,
= large-cell carcinoma; asample includes stage I and II cancer; brecorded mean age where median age was not reported or not extractable, cmedian follow-up
in parenthesis.
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scription of study setting/geographic location, adequate
participation in the study by all eligible patients, reporting
of patients with missing data, a priori and objective defin-
ition of outcomes, and presentation of frequencies of most
important data (for example, outcome) were reported in
all studies. However, baseline sample was adequately
described for key characteristics in 57% (4/7) of the stud-
ies, inclusion and exclusion criteria were adequately
described in 71% (5/7) of the studies, follow-up was suffi-
ciently long for outcome to occur in 86% (6/7) of the stud-
ies, and alpha error and/or beta error were specified a
priori in 29% (2/7) of the studies.
RCTs
All 15 RCTs fulfilled 36% (5/14) of the quality criteria
(Table 1). That is, adequate description of the population
of interest for key characteristics, adequate descriptionof withdrawal (incomplete outcome data), a priori and
objective definition of outcomes, and frequencies of
most important data were reported in all RCTs. How-
ever, study setting and geographic location were ad-
equately described in 47% (7/15) of the RCTs, baseline
sample was adequately described for key characteristics
in 93% (14/15) of the RCTs, inclusion and exclusion cri-
teria were adequately described in 93% (14/15) of the
RCTs, patients were balanced in all aspects except the
intervention in 93% (14/15) of the RCTs, follow-up was
sufficiently long for outcome to occur in 53% (8/15) of
the RCTs, proportion of sample completing the study was
adequate in 60% (9/15) of the RCTs, characteristics of
drop-outs versus completers was provided in 13% (2/15) of
the RCTs, alpha error and/or beta error was specified a
priori in 47% (7/15) of the RCTs, and data analysis was
based on intention-to-treat analysis principle in 53% (9/15)
of the RCTs.
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Cohort
Data on mortality was extractable from all seven cohort
studies enrolling 4,418 patients. As shown in Figure 2,
the pooled proportion of mortality for patients without
anticancer treatment was 0.97 (95% CI: 0.96 to 0.99).
There was a statistically significant heterogeneity among
pooled cohort studies (I-squared = 93%, P <0.00001).
RCTs
Data on mortality was extractable from the control arm
of all 15 RCTs (1,031 patients). Figure 2 shows that the
pooled proportion of mortality for patients in the con-
trol arm (without active treatment) was 0.96 (95% CI:
0.94 to 0.98). There was a statistically significant hetero-
geneity among pooled control arm of RCTs (I-squared =
80%, P <0.00001).
Combined (Cohort and RCTs)
Pooled proportion of mortality across the 22 studies was
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Figure 2 Pooled proportion of mortality in lung cancer studies. The si
(inverse variance).are inherently different from each other, we conducted
separate analyses. However, as shown in Figure 2, testing
for subgroup differences showed no statistically significant
heterogeneity between the two study designs (P = 0.28).
Median survival
Cohort
Data on median overall survival was extractable from
six cohort studies (4,125 patients). As shown in Figure 3,
the pooled mean survival was 11.94 months (95% CI:
10.07 to 13.8). There was a statistically significant het-
erogeneity among pooled cohort studies (I-squared =
97%, P <0.00001).
RCTs
Data on median overall survival was extractable from all 15
RCTs (1,031 patients). The pooled mean survival for
patients in the control arm was 5.03 months (95% CI: 4.17
to 5.89) (Figure 3). There was a statistically significant het-
erogeneity among pooled control arm of RCTs (I-squared =
90%, P <0.00001).01); I² = 93%
01); I² = 80%
0001); I² = 87%
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Test for overall effect: Z = 11.45 (P < 0.00001)
Total (95% CI)
Heterogeneity: Tau² = 8.22; Chi² = 845.73, df = 20 (P < 0.00001); I² = 98%
Test for overall effect: Z = 10.99 (P < 0.00001)
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Figure 3 Pooled mean survival and heterogeneity between subgroups. The size of each square is proportional to the weight of the study
(inverse variance).
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Pooled proportion of mean survival across the 21 studies
was 7.15 months (95% CI: 5.87 to 8.42). Test for sub-
group differences showed statistically significant hetero-
geneity between the two study designs (I-squared =
97.7%, P <0.00001). Thus, the mean survival was influ-
enced by study design (Figure 3).Sensitivity analysis
To assess the robustness of overall results according to
the study design (cohort versus RCT) as well as explore
the reasons for observed heterogeneity in the pooled pro-
portion of mortality and mean survival, we conducted
additional sensitivity analyses. For both cohort studies and
RCTs, we conducted sensitivity analyses according to
methodological quality criteria, funding source, and study
location. For RCTs only, we conducted additional sensitiv-
ity analyses according to type of control. The results of
sensitivity analyses are summarized in Figure 4. Overall,
the results remained unchanged in the sensitivity analyses.
There were no statistically significant differences in the
proportion of mortality.Cohort
In cohort studies, there was no statistically significant dif-
ference in the proportion of mortality according to any
methodological criteria of reporting. With respect to study
location, the pooled proportion of mortality in cohort
studies conducted at multicenter national locations was
0.95 (95% CI: 0.89 to 1.01) and at single institution was
0.98 (95% CI: 0.95 to 1.01) whereas the pooled proportion
of mortality in cohort studies conducted at unspecified
locations was 0.87 (95% CI: 0.82 to 0.93). Test for overall
interaction among these subgroups was statistically signifi-
cant (P = 0.007). Regarding funding source, the pooled
proportion of mortality in public-funded, unspecified fund-
ing sources, and public/industry-funded cohort studies
were 1.00 (95% CI: 1.00 to 1.00), 1.00 (95% CI: 0.99 to
1.00), and 0.97 (95% CI: 0.96 to 0.98), respectively. The test
for overall interaction among these subgroups was statisti-
cally significant (P <0.0001).
RCTs
There was no statistically significant difference in the
proportion of mortality according to methodological cri-
teria of reporting, study location, and funding source.
Figure 4 Pooled proportions of mortality and heterogeneity between subgroups. The size of each square is proportional to the weight of
the study (inverse variance).
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of mortality in RCTs involving best supportive care, no
treatment, placebo, supportive care, and symptomatic
treatment as control were 0.90 (95% CI: 0.83 to 0.97)
and in RCTs involving supportive care as control was
0.96 (95% CI: 0.92 to 1.00), 0.86 (95% CI: 0.81 to 0.92),
1.00 (95% CI: 0.99 to 1.01), 0.96 (95% CI: 0.92 to 1.00),
and 0.97 (95% CI: 0.92 to 1.03), respectively. Test for
overall interaction among these subgroups was statisti-
cally significant (P <0.00001).
We considered performing subgroup analysis based on
median follow-up. However, only one cohort study [32]
and five RCTs [38,39,41,42,45] reported these data. The
median follow-up in the cohort study was 40 months
whereas in the RCTs, the median follow-up was 2.7, 13,
26, 40, and 40 months, respectively. Given that survival
of patients with cancer differs by stage, we considered
performing analysis by cancer stage (I, II, III, versus IV).
However, only two cohort studies (29%) and two RCTs
(13%) reported data by stage. Thus, it was not possible
to perform meta-analysis based on the four stages.
Discussion
This is the first study to provide the most comprehen-
sive data related to survival of lung cancer patients. The
results show that prognosis of patients with lung cancer
not receiving treatment is very high. Regardless of thestudy design (that is, cohort versus RCTs) the findings
were similar and did not differ according to disease se-
verity. For example, all cohort studies assessed mortality
in patients with early stage NSCLC (stage I/II) and all
RCTs enrolled patients with advance stage NSCLC
(stage III/IV). However, the mortality rates from cohort
and RCTs essentially remained unchanged (97% versus
96%). Overall, included studies were of moderate meth-
odological quality.
The findings from our study are similar to the study
by Detterbeck and Gibson [4] which showed a 98% five-
year mortality rate for stage I/II lung cancer (median
survival = 10 months). Despite the obvious similarity in
results our study is significantly different in the conduct
and analysis. For example, the study by Detterbeck and
Gibson [4] did not employ a systematic approach to data
collection and analysis (that is, not a systematic review)
and therefore the findings are not reproducible. The
similarity in findings might be an artifact of play of
chance. Furthermore, quantitative synthesis of results
across included studies was not performed in the study
by Detterbeck and Gibson [4] which was undertaken in
our study. Another unique feature of our study lies in
the inclusion of RCTs in addition to retrospective stud-
ies. None of the previous studies on the topic have uti-
lized the approach of pooling data from one arm of
RCTs for accurate assessment of prognosis. Therefore,
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is the most comprehensive to date in reporting survival
of NSCLC patients without treatment.
Our study has some limitations. For example, we
observed a statistically significant heterogeneity in pooled
results which we could not explain through subgroup ana-
lyses. We suspect that the observed heterogeneity is clin-
ical and not methodological. Specifically in the case of
RCTs, the constitution of control arm varied across pooled
studies. For example, five RCTs employed best supportive
care as control, four had supportive care, two had placebo,
two had no treatment and another two had symptomatic
treatment as control. While, the definitions are very clear
on placebo and no treatment, which was also explained by
the sensitivity analyses (I-squared = 0% for both sub-
groups), the composition of best supportive care, support-
ive care, and symptomatic treatment varied significantly
across pooled studies. In these cases, the observed hetero-
geneity remained unexplained. Also, whereas a significant
number of studies (11 of 15 RCTs) included had some
form of treatment even if used for the purpose of symp-
tom palliation, we were unable to assess the effect of the
supportive treatment on survival based on available data.
Thus, the clinical heterogeneity may be attributed to
stage of disease and/or differential therapies. The studies
included had different follow-up periods, however, due to
limited data reported, we were unable to perform subgroup
analysis based on median follow-up. How much this differ-
ence accounts for results is thus not known. It is also
unclear whether results would have changed had we per-
formed the analysis by cancer stages (I, II, III, versus IV) as
opposed to by stage I/II and III/IV. The former was not
possible due to the limited data reported. Because studies
included enrolled patients with NSCLC, our results may
not entirely apply to all lung cancer patients. However, it is
important to note that a systematic review is limited by the
availability of data and we did include all available data
related to prognosis of NSCLC patients without treatment.
Conclusion
The aim of this review was to estimate overall survival
(natural history) in lung cancer when no anticancer ther-
apy is provided. Our study shows that untreated lung
cancer patients live on average for 7.15 months (95% CI:
5.87 to 8.42). Comprehensive data on the natural history
of lung cancer is required for informed decision making by
patients, physicians and researchers. For patients, it serves
as the basis for their expected outcome with and without
treatment, which is critical in cases of diseases with high
mortality. For physicians, accurate and reliable information
facilitates shared decision making with patients, related to
choice of interventions or no intervention. Most import-
antly, the findings are needed by researchers to avoid opti-
mism bias [8]. A study by Djulbegovic et al. [8] assessedthe role of optimism bias in a cohort of trials conducted by
the National Cancer Institute Cooperative Groups and con-
cluded that optimism bias is the primary reason for in-
conclusive findings in the context of RCTs. Similarly, a
systematic review by Gan and colleagues [9] showed that
investigators tend to make overly optimistic assumptions
regarding treatment benefits when designing RCTs. Ac-
cordingly, the results from our study will help researchers
determine the most optimal rate of expected improvement
in mortality with innovative/newer treatments.
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